{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T03:07:55Z","timestamp":1793070475558,"version":"4.5.0"},"reference-count":224,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T00:00:00Z","timestamp":1558051200000},"content-version":"am","delay-in-days":350,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.pharmthera.2018.01.009","type":"journal-article","created":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T06:37:19Z","timestamp":1517380639000},"page":"152-167","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"special_numbering":"C","title":["The sigma-1 receptor as a regulator of dopamine neurotransmission: A potential therapeutic target for methamphetamine addiction"],"prefix":"10.1016","volume":"186","author":[{"given":"Danielle O.","family":"Sambo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Lebowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habibeh","family":"Khoshbouei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2018.01.009_bb0005","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1365-2125.2012.04333.x","article-title":"Safety, tolerability and pharmacokinetics of single and multiple doses of a novel sigma-1 receptor antagonist in three randomized phase I studies","volume":"75","author":"Abadias","year":"2013","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0010","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0920-9964(94)90035-3","article-title":"Methamphetamine-induced behavioral sensitization and its implications for relapse of schizophrenia","volume":"12","author":"Akiyama","year":"1994","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0015","doi-asserted-by":"crossref","first-page":"7160","DOI":"10.1073\/pnas.1705154114","article-title":"Identification of the gene that codes for the sigma2 receptor","volume":"114","author":"Alon","year":"2017","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0020","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0306-4522(00)00014-2","article-title":"Immunocytochemical localization of the sigma(1) receptor in the adult rat central nervous system","volume":"97","author":"Alonso","year":"2000","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0025","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0896-6273(02)00677-3","article-title":"The sigma receptor as a ligand-regulated auxiliary potassium channel subunit","volume":"34","author":"Aydar","year":"2002","journal-title":"Neuron"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0030","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1016\/0006-2952(73)90147-0","article-title":"Selectivity of release of norepinephrine, dopamine and 5-hydroxytryptamine by amphetamine in various regions of rat brain","volume":"22","author":"Azzaro","year":"1973","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0035","doi-asserted-by":"crossref","first-page":"18219","DOI":"10.1523\/JNEUROSCI.3360-13.2013","article-title":"The sigma-1 receptor interacts directly with GluN1 but not GluN2A in the GluN1\/GluN2A NMDA receptor","volume":"33","author":"Balasuriya","year":"2013","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0040","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cmet.2009.05.009","article-title":"Identification of cholesterol-regulating genes by targeted RNAi screening","volume":"10","author":"Bartz","year":"2009","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0045","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0028-3908(94)00156-M","article-title":"DTG-induced circling behaviour in rats may involve the interaction between sigma sites and nigro-striatal dopaminergic pathways","volume":"34","author":"Bastianetto","year":"1995","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0050","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1196\/annals.1441.031","article-title":"Abuse of amphetamines and structural abnormalities in the brain","volume":"1141","author":"Berman","year":"2008","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0055","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0896-6273(00)80510-3","article-title":"Neuronal calcium signaling","volume":"21","author":"Berridge","year":"1998","journal-title":"Neuron"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0060","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0006-8993(91)90159-S","article-title":"(+)-6,7-benzomorphan sigma ligands stimulate dopamine synthesis in rat corpus striatum tissue","volume":"557","author":"Booth","year":"1991","journal-title":"Brain Research"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0065","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0031-6865(99)00034-5","article-title":"Sigma receptors: Recent advances and new clinical potentials","volume":"74","author":"Bowen","year":"2000","journal-title":"Pharmaceutica Acta Helvetiae"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0070","first-page":"117","article-title":"[3H]-(+)-Pentazocine: A potent and highly selective benzomorphan-based probe for sigma-1 receptors","volume":"3","author":"Bowen","year":"1993","journal-title":"Molecular Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0075","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0022-3565(25)38650-7","article-title":"Further studies of the role of hyperthermia in methamphetamine neurotoxicity","volume":"268","author":"Bowyer","year":"1994","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0080","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ejphar.2006.09.038","article-title":"Interactions between 3,4-methylenedioxymethamphetamine and sigma1 receptors","volume":"553","author":"Brammer","year":"2006","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0085","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/(SICI)1098-2396(199710)27:2<153::AID-SYN6>3.0.CO;2-D","article-title":"Methamphetamine selectively damages dopaminergic innervation to the nucleus accumbens core while sparing the shell","volume":"27","author":"Broening","year":"1997","journal-title":"Synapse"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0090","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/S0022-3565(25)29539-8","article-title":"Dopaminergic neurons: Effect of antipsychotic drugs and amphetamine on single cell activity","volume":"185","author":"Bunney","year":"1973","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0095","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1002\/mds.23263","article-title":"Incidence of Parkinson's disease among hospital patients with methamphetamine-use disorders","volume":"25","author":"Callaghan","year":"2010","journal-title":"Movement Disorders"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0100","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.drugalcdep.2011.06.013","article-title":"Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs","volume":"120","author":"Callaghan","year":"2012","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0105","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/73949","article-title":"A measure of striatal function predicts motor stereotypy","volume":"3","author":"Canales","year":"2000","journal-title":"Nature Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0110","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1021\/jm030008u","article-title":"Dual probes for the dopamine transporter and sigma1 receptors: Novel piperazinyl alkyl-bis(4\u2032-fluorophenyl)amine analogues as potential cocaine-abuse therapeutic agents","volume":"46","author":"Cao","year":"2003","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0115","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0014-2999(88)90362-7","article-title":"Activation of the A10 mesolimbic system by the sigma-receptor agonist (+)SKF 10,047 can be blocked by rimcazole, a novel putative antipsychotic","volume":"154","author":"Ceci","year":"1988","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0120","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1016\/0014-2999(94)90453-7","article-title":"NE-100, a novel potent sigma ligand, preferentially binds to sigma 1 binding sites in guinea pig brain","volume":"251","author":"Chaki","year":"1994","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0125","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.biocel.2004.09.009","article-title":"Dopaminergic neurons","volume":"37","author":"Chinta","year":"2005","journal-title":"The International Journal of Biochemistry & Cell Biology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0130","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.brainresbull.2005.05.028","article-title":"Attenuation of methamphetamine-induced behavioral sensitization in mice by systemic administration of naltrexone","volume":"67","author":"Chiu","year":"2005","journal-title":"Brain Research Bulletin"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0135","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/YCO.0000000000000168","article-title":"Global patterns of methamphetamine use","volume":"28","author":"Chomchai","year":"2015","journal-title":"Current Opinion in Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0140","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.pop.2010.11.004","article-title":"Stimulant abuse: Pharmacology, cocaine, methamphetamine, treatment, attempts at pharmacotherapy","volume":"38","author":"Ciccarone","year":"2011","journal-title":"Primary Care"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0145","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1517\/13543776.2013.769522","article-title":"Sigma receptor modulators: A patent review","volume":"23","author":"Collina","year":"2013","journal-title":"Expert Opinion on Therapeutic Patents"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0150","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.drugalcdep.2014.08.003","article-title":"Methamphetamine: An update on epidemiology, pharmacology, clinical phenomenology, and treatment literature","volume":"143","author":"Courtney","year":"2014","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0155","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0014-2999(99)00828-6","article-title":"Dopamine transporter antagonists block phorbol ester-induced dopamine release and dopamine transporter phosphorylation in striatal synaptosomes","volume":"389","author":"Cowell","year":"2000","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0160","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.drugalcdep.2014.10.027","article-title":"Methamphetamine\/amphetamine abuse and risk of Parkinson's disease in Utah: A population-based assessment","volume":"146","author":"Curtin","year":"2015","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0165","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.2042-7158.1975.tb09502.x","article-title":"Effect of haloperidol on (+)-amphetamine self-administration","volume":"27","author":"Davis","year":"1975","journal-title":"The Journal of Pharmacy and Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0170","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0014-5793(89)81427-9","article-title":"Synthesis and evaluation of optically pure [3H]-(+)-pentazocine, a highly potent and selective radioligand for sigma receptors","volume":"251","author":"de Costa","year":"1989","journal-title":"FEBS Letters"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0175","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0006-3495(96)79604-2","article-title":"Pore models for transporters?","volume":"70","author":"DeFelice","year":"1996","journal-title":"Biophysical Journal"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0180","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1124\/jpet.301.1.306","article-title":"Sigma(2)-receptor regulation of dopamine transporter via activation of protein kinase C","volume":"301","author":"Derbez","year":"2002","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0185","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1073\/pnas.85.14.5274","article-title":"Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats","volume":"85","author":"Di Chiara","year":"1988","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0190","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.phrs.2015.11.021","article-title":"Immunomodulatory effects of fluoxetine: A new potential pharmacological action for a classic antidepressant drug?","volume":"109","author":"Di Rosso","year":"2016","journal-title":"Pharmacological Research"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0195","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1038\/npp.2015.45","article-title":"A single amphetamine infusion reverses deficits in dopamine nerve-terminal function caused by a history of cocaine self-administration","volume":"40","author":"Ferris","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0200","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0022-3565(25)31549-1","article-title":"Chemical release of dopamine from striatal homogenates: Evidence for an exchange diffusion model","volume":"208","author":"Fischer","year":"1979","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0205","doi-asserted-by":"crossref","first-page":"R9","DOI":"10.1016\/S0014-2999(97)00148-9","article-title":"A rapid and reversible change in dopamine transporters induced by methamphetamine","volume":"323","author":"Fleckenstein","year":"1997","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0210","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.neuron.2006.06.028","article-title":"Calmodulin kinase II interacts with the dopamine transporter C terminus to regulate amphetamine-induced reverse transport","volume":"51","author":"Fog","year":"2006","journal-title":"Neuron"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0215","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1126\/science.1166127","article-title":"The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator","volume":"323","author":"Fontanilla","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0220","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1093\/brain\/awu107","article-title":"Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism","volume":"137","author":"Francardo","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0225","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s002130050813","article-title":"Characterization of the sigma ligand panamesine, a potential antipsychotic, by immune response in patients with schizophrenia and by sleep-EEG changes in normal controls","volume":"141","author":"Frieboes","year":"1999","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0230","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s002130050323","article-title":"Open clinical trial on the sigma ligand panamesine in patients with schizophrenia","volume":"132","author":"Frieboes","year":"1997","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0235","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1254\/jjp.54.61","article-title":"Effects of repeated administration of pentazocine on ambulatory activity in mice: Comparison with the effects of morphine and methamphetamine","volume":"54","author":"Fujiwara","year":"1990","journal-title":"Japanese Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0240","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.biopsych.2010.07.026","article-title":"Sigma receptor agonists: Receptor binding and effects on mesolimbic dopamine neurotransmission assessed by microdialysis","volume":"69","author":"Garces-Ramirez","year":"2011","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0245","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/npp.1994.5","article-title":"BMY 14802, a sigma receptor ligand for the treatment of schizophrenia","volume":"10","author":"Gewirtz","year":"1994","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0250","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/0028-3908(92)90049-U","article-title":"Protein kinase C and dopamine transport\u20142. Effects of amphetamine in vitro","volume":"31","author":"Giambalvo","year":"1992","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0255","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/379606a0","article-title":"Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter","volume":"379","author":"Giros","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0260","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1124\/mol.66.1.137","article-title":"Intracellular Ca2+ regulates amphetamine-induced dopamine efflux and currents mediated by the human dopamine transporter","volume":"66","author":"Gnegy","year":"2004","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0265","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S0022-3565(25)22758-6","article-title":"Regulation of [3H]dopamine release from rat striatal slices by sigma receptor ligands","volume":"271","author":"Gonzalez-Alvear","year":"1994","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0270","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1074\/jbc.M805298200","article-title":"Amphetamine and methamphetamine differentially affect dopamine transporters in vitro and in vivo","volume":"284","author":"Goodwin","year":"2009","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0275","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1523\/JNEUROSCI.04-11-02866.1984","article-title":"The control of firing pattern in nigral dopamine neurons: Single spike firing","volume":"4","author":"Grace","year":"1984","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0280","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0014-2999(95)00415-8","article-title":"Effects of sigma receptor ligands on the extracellular concentration of dopamine in the striatum and prefrontal cortex of the rat","volume":"286","author":"Gudelsky","year":"1995","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0285","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s007020050205","article-title":"Biphasic effect of sigma receptor ligands on the extracellular concentration of dopamine in the striatum of the rat","volume":"106","author":"Gudelsky","year":"1999","journal-title":"Journal of Neural Transmission"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0290","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S0161-813X(01)00046-8","article-title":"Is methamphetamine abuse a risk factor in parkinsonism?","volume":"22","author":"Guilarte","year":"2001","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0295","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1523\/JNEUROSCI.06-06-01757.1986","article-title":"Autoradiographic localization of sigma receptor binding sites in guinea pig and rat central nervous system with (+)3H-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine","volume":"6","author":"Gundlach","year":"1986","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0300","first-page":"225","article-title":"Clinical trials with amphetamine-blocking drugs","volume":"75","author":"Gunne","year":"1972","journal-title":"Psychiatria, Neurologia, Neurochirurgia"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0305","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/0092-8674(95)90430-1","article-title":"Decoding of cytosolic calcium oscillations in the mitochondria","volume":"82","author":"Hajnoczky","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0310","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.lfs.2013.07.014","article-title":"Neurotoxicity of methamphetamine and 3,4-methylenedioxymethamphetamine","volume":"97","author":"Halpin","year":"2014","journal-title":"Life Sciences"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0315","doi-asserted-by":"crossref","first-page":"8072","DOI":"10.1073\/pnas.93.15.8072","article-title":"Purification, molecular cloning, and expression of the mammalian sigma1-binding site","volume":"93","author":"Hanner","year":"1996","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0320","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0138959","article-title":"The anti-(+)-methamphetamine monoclonal antibody mAb7F9 attenuates acute (+)-methamphetamine effects on intracranial self-stimulation in rats","volume":"10","author":"Harris","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0325","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1038\/sj.npp.1300223","article-title":"Altering cortisol level does not change the pleasurable effects of methamphetamine in humans","volume":"28","author":"Harris","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0330","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jphs.2014.07.001","article-title":"Sigma-1 receptor: The novel intracellular target of neuropsychotherapeutic drugs","volume":"127","author":"Hayashi","year":"2015","journal-title":"Journal of Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0335","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1124\/jpet.109.159244","article-title":"Regulation of sigma-1 receptors and endoplasmic reticulum chaperones in the brain of methamphetamine self-administering rats","volume":"332","author":"Hayashi","year":"2010","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0340","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0022-3565(25)12037-5","article-title":"Modulation by sigma ligands of intracellular free Ca++ mobilization by N-methyl-d-aspartate in primary culture of rat frontal cortical neurons","volume":"275","author":"Hayashi","year":"1995","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0345","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/S0022-3565(24)39299-7","article-title":"Ca(2+) signaling via sigma(1)-receptors: Novel regulatory mechanism affecting intracellular Ca(2+) concentration","volume":"293","author":"Hayashi","year":"2000","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0350","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1073\/pnas.98.2.491","article-title":"Regulating ankyrin dynamics: Roles of sigma-1 receptors","volume":"98","author":"Hayashi","year":"2001","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0355","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1124\/jpet.103.051292","article-title":"Intracellular dynamics of sigma-1 receptors (sigma(1) binding sites) in NG108-15 cells","volume":"306","author":"Hayashi","year":"2003","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0360","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1124\/jpet.103.051284","article-title":"Sigma-1 receptors (sigma(1) binding sites) form raft-like microdomains and target lipid droplets on the endoplasmic reticulum: Roles in endoplasmic reticulum lipid compartmentalization and export","volume":"306","author":"Hayashi","year":"2003","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0365","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2165\/00023210-200418050-00001","article-title":"Sigma-1 receptor ligands: Potential in the treatment of neuropsychiatric disorders","volume":"18","author":"Hayashi","year":"2004","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0370","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.lfs.2005.05.009","article-title":"The potential role of sigma-1 receptors in lipid transport and lipid raft reconstitution in the brain: Implication for drug abuse","volume":"77","author":"Hayashi","year":"2005","journal-title":"Life Sciences"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0375","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cell.2007.08.036","article-title":"Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival","volume":"131","author":"Hayashi","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0380","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0922-4106(94)90115-5","article-title":"Rat liver and kidney contain high densities of sigma 1 and sigma 2 receptors: Characterization by ligand binding and photoaffinity labeling","volume":"268","author":"Hellewell","year":"1994","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0385","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1124\/jpet.113.208264","article-title":"Preclinical efficacy of N-substituted benztropine analogs as antagonists of methamphetamine self-administration in rats","volume":"348","author":"Hiranita","year":"2014","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0390","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/npp.2012.224","article-title":"Self-administration of cocaine induces dopamine-independent self-administration of sigma agonists","volume":"38","author":"Hiranita","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb9400","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1124\/jpet.111.185025","article-title":"Decreases in cocaine self-administration with dual inhibition of the dopamine transporter and sigma receptors","volume":"339","author":"Hiranita","year":"2011","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb9300","doi-asserted-by":"crossref","DOI":"10.1097\/FBP.0b013e328349ab22","article-title":"Lack of cocaine-like discriminative-stimulus effects of \u03c3-receptor agonists in rats","author":"Hiranita","year":"2011","journal-title":"Behavioral Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0395","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1124\/jpet.113.207522","article-title":"Stimulants as specific inducers of dopamine-independent sigma agonist self-administration in rats","volume":"347","author":"Hiranita","year":"2013","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0400","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.194","article-title":"Sigma-1 receptor deficiency reduces MPTP-induced parkinsonism and death of dopaminergic neurons","volume":"6","author":"Hong","year":"2015","journal-title":"Cell Death & Disease"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0405","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.neurobiolaging.2017.08.007","article-title":"Sigma-1 receptor knockout increases alpha-synuclein aggregation and phosphorylation with loss of dopaminergic neurons in substantia nigra","volume":"59","author":"Hong","year":"2017","journal-title":"Neurobiology of Aging"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0410","doi-asserted-by":"crossref","first-page":"11250","DOI":"10.1074\/jbc.M116.774075","article-title":"The sigma-1 receptor modulates dopamine transporter conformation and cocaine binding and may thereby potentiate cocaine self-administration in rats","volume":"292","author":"Hong","year":"2017","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0415","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0022-3565(25)32165-8","article-title":"Long-term effects of multiple doses of methamphetamine on tryptophan hydroxylase and tyrosine hydroxylase activity in rat brain","volume":"214","author":"Hotchkiss","year":"1980","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0420","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3389\/fnhum.2014.00537","article-title":"The neurobiology of methamphetamine induced psychosis","volume":"8","author":"Hsieh","year":"2014","journal-title":"Frontiers in Human Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0425","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1055\/s-2007-979194","article-title":"Efficacy and safety of the sigma receptor ligand EMD 57445 (panamesine) in patients with schizophrenia: An open clinical trial","volume":"32","author":"Huber","year":"1999","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0430","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1021\/jm9902943","article-title":"Structure-activity relationships at the monoamine transporters and sigma receptors for a novel series of 9-[3-(cis-3, 5-dimethyl-1-piperazinyl)propyl]carbazole (rimcazole) analogues","volume":"42","author":"Husbands","year":"1999","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0435","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1196\/annals.1316.003","article-title":"No association found between the type 1 sigma receptor gene polymorphisms and methamphetamine abuse in the Japanese population: A collaborative study by the Japanese Genetics Initiative for Drug Abuse","volume":"1025","author":"Inada","year":"2004","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0440","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/nn920","article-title":"Dopamine transporter-mediated conductances increase excitability of midbrain dopamine neurons","volume":"5","author":"Ingram","year":"2002","journal-title":"Nature Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0445","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0014-2999(93)90810-5","article-title":"Repeated methamphetamine-treatment alters brain sigma receptors","volume":"230","author":"Itzhak","year":"1993","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0450","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/0006-8993(90)90709-K","article-title":"Sigma receptors modulate both A9 and A10 dopaminergic neurons in the rat brain: Functional interaction with NMDA receptors","volume":"524","author":"Iyengar","year":"1990","journal-title":"Brain Research"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0455","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0014-2999(93)90381-Q","article-title":"Cocaine and several sigma receptor ligands inhibit dopamine uptake in rat caudate-putamen","volume":"243","author":"Izenwasser","year":"1993","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0460","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1096\/fj.03-0295com","article-title":"Methamphetamine induces neuronal apoptosis via cross-talks between endoplasmic reticulum and mitochondria-dependent death cascades","volume":"18","author":"Jayanthi","year":"2004","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0465","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00213-006-0330-6","article-title":"Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers","volume":"185","author":"Johanson","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0470","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1523\/JNEUROSCI.18-06-01979.1998","article-title":"Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter","volume":"18","author":"Jones","year":"1998","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0475","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/BF02244839","article-title":"Influence of naloxone upon motor activity induced by psychomotor stimulant drugs","volume":"114","author":"Jones","year":"1994","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0480","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/cpt1971126889","article-title":"Blockade of intravenous amphetamine euphoria in man","volume":"12","author":"Jonsson","year":"1971","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0485","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1073\/pnas.0407737102","article-title":"Amphetamine induces dopamine efflux through a dopamine transporter channel","volume":"102","author":"Kahlig","year":"2005","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0490","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1365-2125.2010.03639.x","article-title":"Pharmacological approaches to methamphetamine dependence: A focused review","volume":"69","author":"Karila","year":"2010","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0495","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1124\/jpet.116.232728","article-title":"Blockade of cocaine or sigma receptor agonist self administration by subtype-selective sigma receptor antagonists","volume":"358","author":"Katz","year":"2016","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0500","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1208\/s12248-011-9274-9","article-title":"Synthesis and pharmacological evaluation of 6-acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79), a cocaine antagonist, in rodents","volume":"13","author":"Kaushal","year":"2011","journal-title":"The AAPS Journal"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0505","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.euroneuro.2012.08.005","article-title":"Pharmacological evaluation of SN79, a sigma (sigma) receptor ligand, against methamphetamine-induced neurotoxicity in vivo","volume":"23","author":"Kaushal","year":"2013","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0510","doi-asserted-by":"crossref","first-page":"12070","DOI":"10.1074\/jbc.M212815200","article-title":"Amphetamine-induced dopamine efflux. A voltage-sensitive and intracellular Na+-dependent mechanism","volume":"278","author":"Khoshbouei","year":"2003","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0515","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1124\/mol.109.057083","article-title":"Sigma 1 receptor modulation of G-protein-coupled receptor signaling: Potentiation of opioid transduction independent from receptor binding","volume":"77","author":"Kim","year":"2010","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0520","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2012.02.070","article-title":"Sigma-1 receptor alters the kinetics of Kv1.3 voltage gated potassium channels but not the sensitivity to receptor ligands","volume":"1452","author":"Kinoshita","year":"2012","journal-title":"Brain Research"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0525","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/ejn.13363","article-title":"Brain dopamine neurone \u2018damage\u2019: Methamphetamine users vs. Parkinson's disease - a critical assessment of the evidence","volume":"45","author":"Kish","year":"2017","journal-title":"The European Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0530","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00213-008-1425-z","article-title":"Sigma1 receptor antagonists determine the behavioral pattern of the methamphetamine-induced stereotypy in mice","volume":"203","author":"Kitanaka","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0535","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1023\/A:1027361101419","article-title":"Sigma 1 receptor subtype is involved in the facilitation of cortical dopaminergic transmission in the rat brain","volume":"22","author":"Kobayashi","year":"1997","journal-title":"Neurochemical Research"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0540","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/BF01205024","article-title":"The axon initial segment as a synaptic site: Ultrastructure and synaptology of the initial segment of the pyramidal cell in the rat hippocampus (CA3 region)","volume":"9","author":"Kosaka","year":"1980","journal-title":"Journal of Neurocytology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0545","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.cell.2012.12.004","article-title":"Dynamic interaction between sigma-1 receptor and Kv1.2 shapes neuronal and behavioral responses to cocaine","volume":"152","author":"Kourrich","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0550","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.tins.2012.09.007","article-title":"The sigma-1 receptor: Roles in neuronal plasticity and disease","volume":"35","author":"Kourrich","year":"2012","journal-title":"Trends in Neurosciences"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0555","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.brainresrev.2009.03.002","article-title":"Methamphetamine toxicity and messengers of death","volume":"60","author":"Krasnova","year":"2009","journal-title":"Brain Research Reviews"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0560","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1046\/j.1432-1327.1998.2560342.x","article-title":"Antiproliferative effects of SR31747A in animal cell lines are mediated by inhibition of cholesterol biosynthesis at the sterol isomerase step","volume":"256","author":"Labit-Le Bouteiller","year":"1998","journal-title":"European Journal of Biochemistry"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0565","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/09595230801919494","article-title":"A systematic review of cognitive and behavioural therapies for methamphetamine dependence","volume":"27","author":"Lee","year":"2008","journal-title":"Drug and Alcohol Review"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0570","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1146\/annurev.pa.34.040194.001251","article-title":"Permeation properties of neurotransmitter transporters","volume":"34","author":"Lester","year":"1994","journal-title":"Annual Review of Pharmacology and Toxicology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0575","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/syn.21877","article-title":"Cocaine occupancy of sigma1 receptors and dopamine transporters in mice","volume":"70","author":"Lever","year":"2016","journal-title":"Synapse"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0580","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/syn.20253","article-title":"Sigma1 and sigma2 receptor binding affinity and selectivity of SA4503 and fluoroethyl SA4503","volume":"59","author":"Lever","year":"2006","journal-title":"Synapse"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0585","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1124\/jpet.114.216671","article-title":"Relationship between cerebral sigma-1 receptor occupancy and attenuation of cocaine's motor stimulatory effects in mice by PD144418","volume":"351","author":"Lever","year":"2014","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0590","doi-asserted-by":"crossref","first-page":"10376","DOI":"10.1523\/JNEUROSCI.1392-16.2016","article-title":"Methamphetamine regulation of firing activity of dopamine neurons","volume":"36","author":"Lin","year":"2016","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0595","doi-asserted-by":"crossref","first-page":"59345","DOI":"10.18632\/oncotarget.19581","article-title":"Potential independent action of sigma receptor ligands through inhibition of the Kv2.1 channel","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0600","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0022-3565(25)30536-7","article-title":"The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog","volume":"197","author":"Martin","year":"1976","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb9200","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0014-2999(95)00208-3","article-title":"Characterization of two novel sigma receptor ligands: antidystonic effects in rats suggest sigma receptor antagonism","volume":"280","author":"Matsumoto","year":"1995","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0605","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0014-2999(03)01723-0","article-title":"Sigma receptors: Potential medications development target for anti-cocaine agents","volume":"469","author":"Matsumoto","year":"2003","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0610","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0028-3908(02)00056-4","article-title":"Involvement of sigma receptors in the behavioral effects of cocaine: Evidence from novel ligands and antisense oligodeoxynucleotides","volume":"42","author":"Matsumoto","year":"2002","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0615","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.euroneuro.2008.07.006","article-title":"Attenuation of methamphetamine-induced effects through the antagonism of sigma (sigma) receptors: Evidence from in vivo and in vitro studies","volume":"18","author":"Matsumoto","year":"2008","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0620","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0014-2999(96)00201-4","article-title":"Binding properties of SA4503, a novel and selective sigma 1 receptor agonist","volume":"306","author":"Matsuno","year":"1996","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0625","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0149-7634(02)00017-9","article-title":"Sigma(1) (sigma(1)) receptor antagonists represent a new strategy against cocaine addiction and toxicity","volume":"26","author":"Maurice","year":"2002","journal-title":"Neuroscience and Biobehavioral Reviews"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0630","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/(SICI)1097-4547(19961215)46:6<734::AID-JNR10>3.0.CO;2-U","article-title":"Modulation by neurosteroids of the in vivo (+)-[3H]SKF-10,047 binding to sigma 1 receptors in the mouse forebrain","volume":"46","author":"Maurice","year":"1996","journal-title":"Journal of Neuroscience Research"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0635","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.neuroscience.2010.02.022","article-title":"The sigma-1 receptor is enriched in postsynaptic sites of C-terminals in mouse motoneurons. An anatomical and behavioral study","volume":"167","author":"Mavlyutov","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0640","doi-asserted-by":"crossref","first-page":"10689","DOI":"10.1038\/srep10689","article-title":"Subcellular localization of the sigma-1 receptor in retinal neurons - an electron microscopy study","volume":"5","author":"Mavlyutov","year":"2015","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0645","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.addbeh.2011.07.017","article-title":"Methamphetamine: Here we go again?","volume":"36","author":"Maxwell","year":"2011","journal-title":"Addictive Behaviors"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0650","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0922-4106(90)90004-H","article-title":"Haloperidol-sensitive (+)[3H]SKF-10,047 binding sites (sigma sites) exhibit a unique distribution in rat brain subcellular fractions","volume":"188","author":"McCann","year":"1990","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0655","doi-asserted-by":"crossref","first-page":"8417","DOI":"10.1523\/JNEUROSCI.18-20-08417.1998","article-title":"Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: Evidence from positron emission tomography studies with [11C]WIN-35,428","volume":"18","author":"McCann","year":"1998","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb9100","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0014-2999(98)00876-0","article-title":"Novel sigma receptor ligands attenuate the locomotor stimulatory effects of cocaine","volume":"365","author":"McCracken","year":"1999","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0660","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0306-4522(88)90024-3","article-title":"Autoradiographic visualization of haloperidol-sensitive sigma receptors in guinea-pig brain","volume":"25","author":"McLean","year":"1988","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0665","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1124\/jpet.300.3.1070","article-title":"Sigma1 receptor modulation of opioid analgesia in the mouse","volume":"300","author":"Mei","year":"2002","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0670","doi-asserted-by":"crossref","first-page":"7699","DOI":"10.1523\/JNEUROSCI.19-18-07699.1999","article-title":"Membrane trafficking regulates the activity of the human dopamine transporter","volume":"19","author":"Melikian","year":"1999","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0675","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.pbb.2016.11.003","article-title":"N-phenylpropyl-N\u2032-substituted piperazines occupy sigma receptors and alter methamphetamine-induced hyperactivity in mice","volume":"150-151","author":"Miller","year":"2016","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0680","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/(SICI)1098-2396(199908)33:2<129::AID-SYN3>3.0.CO;2-E","article-title":"Acute and chronic administration of the selective sigma1 receptor agonist SA4503 significantly alters the activity of midbrain dopamine neurons in rats: An in vivo electrophysiological study","volume":"33","author":"Minabe","year":"1999","journal-title":"Synapse"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0685","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1600-0404.2005.00432.x","article-title":"Function of sigma1 receptors in Parkinson's disease","volume":"112","author":"Mishina","year":"2005","journal-title":"Acta Neurologica Scandinavica"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0690","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0028-3908(03)00253-3","article-title":"Intrastriatal administration of sigma ligands inhibits basal dopamine release in vivo","volume":"45","author":"Moison","year":"2003","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0695","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00004714-200102000-00011","article-title":"Opipramol for the treatment of generalized anxiety disorder: A placebo-controlled trial including an alprazolam-treated group","volume":"21","author":"Moller","year":"2001","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0700","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1034\/j.1601-5215.2003.00030.x","article-title":"Psychopharmacotherapy of somatoform disorders: Effects of opipramol on symptoms of somatization, anxiety, and depression","volume":"15","author":"Moller","year":"2003","journal-title":"Acta Neuropsychiatrica"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0705","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076941","article-title":"Sigma-1 receptor chaperone at the ER-mitochondrion interface mediates the mitochondrion-ER-nucleus signaling for cellular survival","volume":"8","author":"Mori","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0710","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/j.1369-1600.2012.00488.x","article-title":"Inhibitory effects of SA4503 on the rewarding effects of abused drugs","volume":"19","author":"Mori","year":"2014","journal-title":"Addiction Biology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0715","doi-asserted-by":"crossref","first-page":"8480","DOI":"10.1523\/JNEUROSCI.23-24-08480.2003","article-title":"Mitogen-activated protein kinase regulates dopamine transporter surface expression and dopamine transport capacity","volume":"23","author":"Moron","year":"2003","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0720","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/j.neubiorev.2013.05.002","article-title":"Using conditioned place preference to identify relapse prevention medications","volume":"37","author":"Napier","year":"2013","journal-title":"Neuroscience and Biobehavioral Reviews"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0725","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0014-2999(96)00254-3","article-title":"Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain","volume":"307","author":"Narita","year":"1996","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0730","doi-asserted-by":"crossref","first-page":"18676","DOI":"10.1073\/pnas.1008911107","article-title":"Direct involvement of sigma-1 receptors in the dopamine D1 receptor-mediated effects of cocaine","volume":"107","author":"Navarro","year":"2010","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0735","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061245","article-title":"Cocaine inhibits dopamine D2 receptor signaling via sigma-1-D2 receptor heteromers","volume":"8","author":"Navarro","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0740","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.neuropharm.2005.04.016","article-title":"Involvement of sigma (sigma) receptors in the acute actions of methamphetamine: Receptor binding and behavioral studies","volume":"49","author":"Nguyen","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0745","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/JCP.0b013e3182664cfc","article-title":"A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: A preliminary study","volume":"32","author":"Niitsu","year":"2012","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0750","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3389\/fncel.2013.00050","article-title":"The essential roles of protein-protein interaction in sigma-1 receptor functions","volume":"7","author":"Pabba","year":"2013","journal-title":"Frontiers in Cellular Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0755","doi-asserted-by":"crossref","first-page":"11325","DOI":"10.1523\/JNEUROSCI.0458-14.2014","article-title":"NMDA receptors are upregulated and trafficked to the plasma membrane after sigma-1 receptor activation in the rat hippocampus","volume":"34","author":"Pabba","year":"2014","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0760","doi-asserted-by":"crossref","first-page":"11166","DOI":"10.1158\/0008-5472.CAN-07-1771","article-title":"Sigma-1 receptors bind cholesterol and remodel lipid rafts in breast cancer cell lines","volume":"67","author":"Palmer","year":"2007","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0765","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.drugalcdep.2012.11.016","article-title":"Methamphetamine use: A comprehensive review of molecular, preclinical and clinical findings","volume":"129","author":"Panenka","year":"2013","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0770","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0014-2999(93)90456-R","article-title":"Increases in rat striatal extracellular dopamine and vacuous chewing produced by two sigma receptor ligands","volume":"231","author":"Patrick","year":"1993","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0775","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1096\/fasebj.7.12.8375616","article-title":"Sigma receptors modulate nicotinic receptor function in adrenal chromaffin cells","volume":"7","author":"Paul","year":"1993","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0780","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0165-6147(92)90030-A","article-title":"A proposal for the classification of sigma binding sites","volume":"13","author":"Quirion","year":"1992","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0785","first-page":"49","article-title":"Involvement of sigma 1 receptor in the SSRI-induced suppression of the methamphetamine-induced behavioral sensitization and rewarding effects in mice","volume":"33","author":"Rahmadi","year":"2013","journal-title":"Nihon Shinkei Seishin Yakurigaku Zasshi"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2018.01.009_bb0790","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1360-0443.2006.01781.x","article-title":"Why do we need an Addiction supplement focused on methamphetamine?","volume":"102","author":"Rawson","year":"2007","journal-title":"Addiction"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0795","doi-asserted-by":"crossref","first-page":"10423","DOI":"10.1038\/ncomms10423","article-title":"Membrane potential shapes regulation of dopamine transporter trafficking at the plasma membrane","volume":"7","author":"Richardson","year":"2016","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0800","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.pbb.2010.11.016","article-title":"SA 4503 attenuates cocaine-induced hyperactivity and enhances methamphetamine substitution for a cocaine discriminative stimulus","volume":"97","author":"Rodvelt","year":"2011","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0805","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.drugalcdep.2010.12.018","article-title":"The sigma receptor agonist SA4503 both attenuates and enhances the effects of methamphetamine","volume":"116","author":"Rodvelt","year":"2011","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0810","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1083\/jcb.13.3.405","article-title":"Subsurface cisterns and their relationship to the neuronal plasma membrane","volume":"13","author":"Rosenbluth","year":"1962","journal-title":"The Journal of Cell Biology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0815","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10799893.2015.1015737","article-title":"Sigma receptors [sigmaRs]: Biology in normal and diseased states","author":"Rousseaux","year":"2015","journal-title":"Journal of Receptor and Signal Transduction Research"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0820","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/hipo.20273","article-title":"Steroid pregnenolone sulfate enhances NMDA-receptor-independent long-term potentiation at hippocampal CA1 synapses: Role for L-type calcium channels and sigma-receptors","volume":"17","author":"Sabeti","year":"2007","journal-title":"Hippocampus"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0825","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.bbr.2008.11.036","article-title":"Sigma-1 receptor knockout mice display a depressive-like phenotype","volume":"198","author":"Sabino","year":"2009","journal-title":"Behavioural Brain Research"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0830","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.phrs.2016.05.031","article-title":"Are fluoxetine's effects due to sigma-1 receptor agonism?","volume":"113","author":"Safrany","year":"2016","journal-title":"Pharmacological Research"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0835","doi-asserted-by":"crossref","first-page":"22246","DOI":"10.1074\/jbc.M114.563056","article-title":"Intracellular methamphetamine prevents the dopamine-induced enhancement of neuronal firing","volume":"289","author":"Saha","year":"2014","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0840","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1021\/acschemneuro.7b00200","article-title":"Sigma 2 receptor\/Tmem97 agonists produce long lasting anti-neuropathic pain effects in mice","volume":"8","author":"Sahn","year":"2017","journal-title":"ACS Chemical Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0845","first-page":"445","article-title":"Impact of methamphetamine on infection and immunity","volume":"8","author":"Salamanca","year":"2014","journal-title":"Frontiers in Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0850","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1038\/s41467-017-02087-x","article-title":"The sigma-1 receptor modulates methamphetamine dysregulation of dopamine neurotransmission","volume":"8","author":"Sambo","year":"2017","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0855","series-title":"National survey on drug use","author":"SAMHSA","year":"2006"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0860","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/nature17391","article-title":"Crystal structure of the human sigma1 receptor","volume":"532","author":"Schmidt","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0865","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0022-3565(25)29318-1","article-title":"Amphetamine-induced exocytosis of catecholamines from the cow adrenal medulla","volume":"183","author":"Schneider","year":"1972","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0870","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.pbb.2010.11.023","article-title":"Sigma (sigma) receptor ligand, AC927 (N-phenethylpiperidine oxalate), attenuates methamphetamine-induced hyperthermia and serotonin damage in mice","volume":"98","author":"Seminerio","year":"2011","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0875","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1208\/s12248-011-9311-8","article-title":"Synthesis and pharmacological characterization of a novel sigma receptor ligand with improved metabolic stability and antagonistic effects against methamphetamine","volume":"14","author":"Seminerio","year":"2012","journal-title":"The AAPS Journal"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0880","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0014-2999(88)90058-1","article-title":"Cocaine binding at sigma receptors","volume":"149","author":"Sharkey","year":"1988","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0885","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jsat.2006.06.012","article-title":"Psychosocial approaches to psychostimulant dependence: A systematic review","volume":"32","author":"Shearer","year":"2007","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0890","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1002\/jnr.22386","article-title":"mu-Opioid receptor knockout mice are insensitive to methamphetamine-induced behavioral sensitization","volume":"88","author":"Shen","year":"2010","journal-title":"Journal of Neuroscience Research"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0895","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1523\/JNEUROSCI.20-09-03504.2000","article-title":"Dual effects of d-amphetamine on dopamine neurons mediated by dopamine and nondopamine receptors","volume":"20","author":"Shi","year":"2000","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0900","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.neulet.2010.06.069","article-title":"Inhibition of sigma-1 receptor reduces N-methyl-d-aspartate induced neuronal injury in methamphetamine-exposed and -naive hippocampi","volume":"481","author":"Smith","year":"2010","journal-title":"Neuroscience Letters"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0905","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1523\/JNEUROSCI.17-03-00960.1997","article-title":"Multiple ionic conductances of the human dopamine transporter: The actions of dopamine and psychostimulants","volume":"17","author":"Sonders","year":"1997","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0910","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1126\/science.2563176","article-title":"Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity","volume":"243","author":"Sonsalla","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0915","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1523\/JNEUROSCI.17-01-00190.1997","article-title":"Three-dimensional organization of smooth endoplasmic reticulum in hippocampal CA1 dendrites and dendritic spines of the immature and mature rat","volume":"17","author":"Spacek","year":"1997","journal-title":"The Journal of Neuroscience: the Official Journal of the Society for Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0920","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1083\/jcb.201506022","article-title":"Sigma1 receptors inhibit store-operated Ca2+ entry by attenuating coupling of STIM1 to Orai1","volume":"213","author":"Srivats","year":"2016","journal-title":"The Journal of Cell Biology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0925","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s00213-004-1779-9","article-title":"Sigma1 receptor upregulation after chronic methamphetamine self-administration in rats: A study with yoked controls","volume":"175","author":"Stefanski","year":"2004","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0930","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0014-2999(89)90413-5","article-title":"Selective sigma receptor agonist and antagonist affect dopamine neuronal activity","volume":"163","author":"Steinfels","year":"1989","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0935","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0022-3565(25)33330-6","article-title":"Evidence for sigma opioid receptor: Binding of [3H]SKF-10047 to etorphine-inaccessible sites in guinea-pig brain","volume":"223","author":"Su","year":"1982","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0940","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.2174\/0929867033456783","article-title":"Understanding the molecular mechanism of sigma-1 receptors: Towards a hypothesis that sigma-1 receptors are intracellular amplifiers for signal transduction","volume":"10","author":"Su","year":"2003","journal-title":"Current Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0945","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.tips.2010.08.007","article-title":"The sigma-1 receptor chaperone as an inter-organelle signaling modulator","volume":"31","author":"Su","year":"2010","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0950","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1126\/science.2832949","article-title":"Steroid binding at sigma receptors suggests a link between endocrine, nervous, and immune systems","volume":"240","author":"Su","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0955","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/0014-2999(88)90130-6","article-title":"Correlation of inhibitory potencies of putative antagonists for sigma receptors in brain and spleen","volume":"148","author":"Su","year":"1988","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0960","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0022-3565(25)20283-X","article-title":"Sigma compounds derived from phencyclidine: Identification of PRE-084, a new, selective sigma ligand","volume":"259","author":"Su","year":"1991","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0965","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1523\/JNEUROSCI.15-05-04102.1995","article-title":"Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport","volume":"15","author":"Sulzer","year":"1995","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0970","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1471-4159.1993.tb03181.x","article-title":"Amphetamine and other weak bases act to promote reverse transport of dopamine in ventral midbrain neurons","volume":"60","author":"Sulzer","year":"1993","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0975","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/0896-6273(90)90339-H","article-title":"Amphetamine and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: A mechanism of action","volume":"5","author":"Sulzer","year":"1990","journal-title":"Neuron"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0980","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.pneurobio.2005.04.003","article-title":"Mechanisms of neurotransmitter release by amphetamines: A review","volume":"75","author":"Sulzer","year":"2005","journal-title":"Progress in Neurobiology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0985","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0304-3940(00)01258-1","article-title":"Involvement of sigma 1 receptors in methamphetamine-induced behavioral sensitization in rats","volume":"289","author":"Takahashi","year":"2000","journal-title":"Neuroscience Letters"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0990","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s002130051061","article-title":"Pharmacological profile of MS-377, a novel antipsychotic agent with selective affinity for sigma receptors","volume":"145","author":"Takahashi","year":"1999","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb0995","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1167\/iovs.08-1867","article-title":"Sigma-1 receptor regulation of voltage-gated calcium channels involves a direct interaction","volume":"49","author":"Tchedre","year":"2008","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb1000","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2174\/1871524910909030184","article-title":"Sigma-1 receptor chaperones and diseases","volume":"9","author":"Tsai","year":"2009","journal-title":"Central Nervous System Agents in Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb1005","doi-asserted-by":"crossref","first-page":"PL129","DOI":"10.1016\/0024-3205(92)90466-3","article-title":"Sigma (sigma) antagonist BMY 14802 prevents methamphetamine-induced sensitization","volume":"50","author":"Ujike","year":"1992","journal-title":"Life Sciences"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb1010","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0014-2999(92)90388-K","article-title":"Persistent supersensitivity of sigma receptors develops during repeated methamphetamine treatment","volume":"211","author":"Ujike","year":"1992","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb1015","series-title":"World drug report","author":"UNODC","year":"2016"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb1020","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0014-2999(83)90297-2","article-title":"Naltrexone fails to antagonize the sigma effects of PCP and SKF 10,047 in the dog","volume":"92","author":"Vaupel","year":"1983","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb1025","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.disamonth.2011.09.004","article-title":"Methamphetamine: History, pathophysiology, adverse health effects, current trends, and hazards associated with the clandestine manufacture of methamphetamine","volume":"58","author":"Vearrier","year":"2012","journal-title":"Disease-a-Month"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb1030","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1176\/appi.ajp.158.12.2015","article-title":"Low level of brain dopamine D2 receptors in methamphetamine abusers: Association with metabolism in the orbitofrontal cortex","volume":"158","author":"Volkow","year":"2001","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb1035","doi-asserted-by":"crossref","first-page":"9414","DOI":"10.1523\/JNEUROSCI.21-23-09414.2001","article-title":"Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence","volume":"21","author":"Volkow","year":"2001","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb1040","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1176\/appi.ajp.158.3.377","article-title":"Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers","volume":"158","author":"Volkow","year":"2001","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb1045","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1001\/archneur.64.11.1575","article-title":"Dopamine in drug abuse and addiction: Results of imaging studies and treatment implications","volume":"64","author":"Volkow","year":"2007","journal-title":"Archives of Neurology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb1050","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0022-3565(24)35115-8","article-title":"Reinforcing effects of psychostimulants in humans are associated with increases in brain dopamine and occupancy of D(2) receptors","volume":"291","author":"Volkow","year":"1999","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb1055","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0924-977X(00)00074-2","article-title":"Opipramol for the treatment of somatoform disorders results from a placebo-controlled trial","volume":"10","author":"Volz","year":"2000","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb1060","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0022-3565(25)24245-8","article-title":"Electrophysiological effects of BMY 14802, a new potential antipsychotic drug, on midbrain dopamine neurons in the rat: Acute and chronic studies","volume":"244","author":"Wachtel","year":"1988","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb1065","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0014-2999(93)90684-A","article-title":"A comparison of (\u2212)-deoxybenzomorphans devoid of opiate activity with their dextrorotatory phenolic counterparts suggests role of sigma 2 receptors in motor function","volume":"231","author":"Walker","year":"1993","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb1070","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1016\/S0968-0896(02)00043-3","article-title":"Conformationally constrained ethylenediamines: Synthesis and receptor binding of 6,8-diazabicyclo[3.2.2]nonanes","volume":"10","author":"Weigl","year":"2002","journal-title":"Bioorganic & Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb1075","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0006-8993(84)90594-8","article-title":"Electrophysiological evidence for A10 dopamine autoreceptor subsensitivity following chronic d-amphetamine treatment","volume":"309","author":"White","year":"1984","journal-title":"Brain Research"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb1080","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0022-3565(25)10260-7","article-title":"Differential development of autoreceptor subsensitivity and enhanced dopamine release during amphetamine sensitization","volume":"264","author":"Wolf","year":"1993","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb1085","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1124\/mol.116.104018","article-title":"Aberrant subcellular dynamics of sigma-1 receptor mutants underlying neuromuscular diseases","volume":"90","author":"Wong","year":"2016","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb1090","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1124\/jpet.109.161398","article-title":"A novel substituted piperazine, CM156, attenuates the stimulant and toxic effects of cocaine in mice","volume":"333","author":"Xu","year":"2010","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb1095","doi-asserted-by":"crossref","DOI":"10.4303\/jdar\/235970","article-title":"Potential molecular mechanisms on the role of the sigma-1 receptor in the action of cocaine and methamphetamine","volume":"5","author":"Yasui","year":"2016","journal-title":"Journal of Drug Alcohol Research"},{"key":"10.1016\/j.pharmthera.2018.01.009_bb1100","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1126\/science.1114313","article-title":"Increased lever pressing for amphetamine after pimozide in rats: Implications for a dopamine theory of reward","volume":"187","author":"Yokel","year":"1975","journal-title":"Science"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725818300160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725818300160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:53:08Z","timestamp":1759009988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725818300160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":224,"alternative-id":["S0163725818300160"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2018.01.009","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The sigma-1 receptor as a regulator of dopamine neurotransmission: A potential therapeutic target for methamphetamine addiction","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2018.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}